Cargando…

Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019

BACKGROUND: “As part of the U.S. government's urgent response to the epidemic of overdose deaths (1)” the United States Centers for Disease Control and Prevention (CDC) issued the “CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016 (2)” (guideline) followed by the “CDC C...

Descripción completa

Detalles Bibliográficos
Autores principales: Aubry, Larry, Carr, B. Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385960/
https://www.ncbi.nlm.nih.gov/pubmed/35992020
http://dx.doi.org/10.3389/fpain.2022.884674
_version_ 1784769694561992704
author Aubry, Larry
Carr, B. Thomas
author_facet Aubry, Larry
Carr, B. Thomas
author_sort Aubry, Larry
collection PubMed
description BACKGROUND: “As part of the U.S. government's urgent response to the epidemic of overdose deaths (1)” the United States Centers for Disease Control and Prevention (CDC) issued the “CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016 (2)” (guideline) followed by the “CDC Clinical Practice Guideline for Prescribing Opioids–United States, 2022 (3) (guideline update). ” The guideline and guideline update cite a direct correlation between prescription opioids sales (POS) and opioid treatment admissions (OTA) and prescription opioid deaths (POD), which was based on data from 1999 to 2010. This paper updates those relationships and includes the correlations between prescription opioid sales (POS) and any opioid deaths (AOD) and total overdose deaths (TOD) from 2010 to 2019. METHODS: Linear regression models were fit to each response separately. Opioid sales (measured as MME (morphine milligram equivalent) per capita) was the independent variable. Total overdose deaths (TOD), any opioid overdose deaths (AOD), prescription opioid overdose deaths (POD) and opioid treatment admissions (OTA) were the dependent, response variables. The models were assessed using three criteria: the statistical significance of the model (Overall P-Value), the quality of the fit (R(2)), and the sign of the slope coefficient (positive or negative). RESULTS: The analyses revealed that the direct correlations (i.e., significant, positive slopes) reported by the CDC based on data from 1999 to 2010 no longer exist. Based on data from 2010 to 2019, the relationships either have reversed (i.e., significant, negative slopes) or are non-existent (i.e., no significant model). CONCLUSIONS: The guideline, guideline update, CDC's public, medical profession, and intergovernmental communications should be corrected/updated to state no direct correlation has existed between POS to OTA, POD, AOD, and TOD since 2010. Individualized patient care and public health policy should be amended accordingly.
format Online
Article
Text
id pubmed-9385960
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93859602022-08-19 Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019 Aubry, Larry Carr, B. Thomas Front Pain Res (Lausanne) Pain Research BACKGROUND: “As part of the U.S. government's urgent response to the epidemic of overdose deaths (1)” the United States Centers for Disease Control and Prevention (CDC) issued the “CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016 (2)” (guideline) followed by the “CDC Clinical Practice Guideline for Prescribing Opioids–United States, 2022 (3) (guideline update). ” The guideline and guideline update cite a direct correlation between prescription opioids sales (POS) and opioid treatment admissions (OTA) and prescription opioid deaths (POD), which was based on data from 1999 to 2010. This paper updates those relationships and includes the correlations between prescription opioid sales (POS) and any opioid deaths (AOD) and total overdose deaths (TOD) from 2010 to 2019. METHODS: Linear regression models were fit to each response separately. Opioid sales (measured as MME (morphine milligram equivalent) per capita) was the independent variable. Total overdose deaths (TOD), any opioid overdose deaths (AOD), prescription opioid overdose deaths (POD) and opioid treatment admissions (OTA) were the dependent, response variables. The models were assessed using three criteria: the statistical significance of the model (Overall P-Value), the quality of the fit (R(2)), and the sign of the slope coefficient (positive or negative). RESULTS: The analyses revealed that the direct correlations (i.e., significant, positive slopes) reported by the CDC based on data from 1999 to 2010 no longer exist. Based on data from 2010 to 2019, the relationships either have reversed (i.e., significant, negative slopes) or are non-existent (i.e., no significant model). CONCLUSIONS: The guideline, guideline update, CDC's public, medical profession, and intergovernmental communications should be corrected/updated to state no direct correlation has existed between POS to OTA, POD, AOD, and TOD since 2010. Individualized patient care and public health policy should be amended accordingly. Frontiers Media S.A. 2022-08-04 /pmc/articles/PMC9385960/ /pubmed/35992020 http://dx.doi.org/10.3389/fpain.2022.884674 Text en Copyright © 2022 Aubry and Carr. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pain Research
Aubry, Larry
Carr, B. Thomas
Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019
title Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019
title_full Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019
title_fullStr Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019
title_full_unstemmed Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019
title_short Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019
title_sort overdose, opioid treatment admissions and prescription opioid pain reliever relationships: united states, 2010–2019
topic Pain Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385960/
https://www.ncbi.nlm.nih.gov/pubmed/35992020
http://dx.doi.org/10.3389/fpain.2022.884674
work_keys_str_mv AT aubrylarry overdoseopioidtreatmentadmissionsandprescriptionopioidpainrelieverrelationshipsunitedstates20102019
AT carrbthomas overdoseopioidtreatmentadmissionsandprescriptionopioidpainrelieverrelationshipsunitedstates20102019